U.S. stocks fell on Monday, with the Dow Jones Industrial Average stepping back from an all-time high, as uncertainty about China's growth injected caution into global markets. Stocks' cautious tone began overnight, after China's financial minister said that major changes to the country's economic stimulus efforts aren't likely even as the world's second-largest economy grapples with growth concerns.

That statement damped hopes for more aggressive policies, and also pushed Treasurys higher, while driving copper and nickel lower.

Genetic Technologies Limited (ADR)(NASDAQ:GENE) sells its heritage Australian Genetics business to Primary Heath Care Ltd. subsidiary Specialist Services Ltd. for $2M in cash. The Australian Genetics operation provides diagnostic and sequencing services focused on Australia-only medical, forensic, paternity and animal genomic testing.The transaction is part of the company's plan to divest non-core assets and focus its activities on the U.S. molecular diagnostics market and its lead breast cancer risk test BREVAGen.

Lead Investigator Daniel Pryma, M.D., Associate Professor of Radiology and Clinical Director of Nuclear Medicine and Molecular Imaging, Department of Radiology at the University of Pennsylvania gave an oral presentation today at the International Symposium of Pheochromocytoma and Paraganglioma in Kyoto, Japan on data from a Phase 2 trial of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Azedra (Ultratrace Iobenguane I-131).

Repros Therapeutics Inc. (NASDAQ:RPRX) says that since its lead candidate Androxal (isomer of clomiphene citrate) is not a form of testosterone, last week's joint Ad Comm meeting's position recommending a revision of TRT treatment class labeling does not apply to its product.

Under expanded access protocols approved by the FDA and HEALTH Canada, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) can now provide TKM-Ebola to patients with confirmed or suspected Ebola Virus infections. President and CEO Dr. Mark J. Murray says, "Our TKM-Ebola drug supplies are limited, but we will continue to help where we can as we continue to focus on the other important objectives we have to advance therapies to meet the unmet needs of patients."

Based on an interim efficacy and safety analysis, the Independent Data Monitoring Committee IDMC recommends the Phase 3 clinical trial of Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) TH-302 continue as planned.